Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 91

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 91
---
. Davis was appointed as a director of the Company on December 10, 2024. Amount shown reflects the grant date fair value of an award of 22,816 RSUs calculated in accordance with FASB ASC Topic 718. The grant date fair value was determined by multiplying the number of shares by $15.34, the closing price of our common stock on the Nasdaq Global Select Market on December 10, 2024, the date of the grant. These RSUs awarded to Mr. Davis vest on December 10, 2025.                                                                                                                                                                      |     |                  |     |             |     |           |
| (3) Mr. Spiegelman's term as a director expired on June 6, 2024.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |     |                  |     |             |     |           |

The following table shows unvested RSUs for each non-employee director as of December 31, 2024.

|                                   |     | Unvested |
| Name                              |     |     RSUs |
| Paul Bisaro                       |     |   15,695 |
| Heiner Dreismann, Ph.D.           |     |   15,695 |
| Rashmi Kumar                      |     |   15,695 |
| Lee N. Newcomer, M.D.             |     |   15,695 |
| S. Louise Phanstiel               |     |   15,695 |
| Colleen F. Reitan                 |     |   15,695 |
| Daniel M. Skovronsky, M.D., Ph.D. |     |   15,695 |
| Mark S. Davis                     |     |   22,816 |

Director Compensation Policy

Our non-employee directors are compensated on a role-based model and are paid cash fees based on annual retainers (25% paid following each quarter of service) for their service on our Board. Mr. Diaz, our Chief Executive Officer, is a member of our Board but is employed by us, and, as such, he receives no additional compensation for his service on our Board.

61

Attracting and retaining qualified non-employee directors is critical to the governance and long-term success of the Company. As a result, the CHCC, in consultation with its outside compensation consultant, regularly reviews our director compensation to ensure that it is competitive with our peer group of companies.

The following is a description of the standard compensation arrangements under which our non